Fred Eshelman, PharmD - Board Chairman
Dr. Eshelman is the founder and principal of Eshelman Ventures LLC, investing in a variety of companies, primarily health care. Previously, he was the founding Chairman of Furiex Pharmaceuticals, which was sold to Forest Labs/Actavis in 2014. Dr. Eshelman also founded and served as CEO and Executive Chairman for Pharmaceutical Product Development, Inc. until the sale of the company to private equity interests (Carlyle, Hellman & Friedman). His career also included positions as Senior Vice President, Development and board member at Glaxo, Inc., as well as various management positions at Beecham Laboratories and Boehringer Mannheim Pharmaceuticals. Dr. Eshelman is part of several industry boards and has served on the executive committee of the Medical Foundation of North Carolina and the board of the North Carolina Biotechnology Center.
Dr. Eshelman is also active in higher education, serving on the Board of Governors for the University of North Carolina (UNC) System (audit committee chair) and as an adjunct professor at the UNC School of Pharmacy, where he chairs the Board of Visitors. One of the top pharmacy programs in the US, the school was named the Eshelman School of Pharmacy in 2008, in recognition of his many contributions to the school and profession. Dr. Eshelman has received numerous awards, including the Davie and Outstanding Service awards from UNC, Chapel Hill and outstanding alumnus awards from UNC and the University of Cincinnati schools of pharmacy. He also received the Ernst & Young Entrepreneur of the Year, North Carolina Entrepreneur Hall of Fame award, and was awarded an honorary Doctor of Science degree from UNC Chapel Hill.
Dr. Eshelman holds a PharmD degree from the University of Cincinnati and completed a hospital residency at Cincinnati General Hospital. He has a Bachelor’s degree in pharmacy from UNC at Chapel Hill. In addition, he has completed the Owner/President Management program at Harvard Business School.
Robert Bonczek, JD, MBA
Mr. Bonczek is Chief Financial Officer and a director of Cellective BioTherapy, Inc. He also serves as Chief Administrative Officer at Istari Oncology, Inc. and President and Chief Financial Officer of MedBlue Incubator, Inc. Mr. Bonczek has served as President, Director, CFO and General Counsel of b3 bio, Inc.; CFO, General Counsel and Chief Administrative Officer of Trimeris, Inc.; and Chief Counsel and Global Director of Safety, Health and Environment, Dupont. Mr. Bonczek is founding partner, Director and President of Aspen Tree Capital. He also serves on the boards of several life science-related companies including NeurOp, Inc., Senex Biotechnology, Upstream Therapeutics, Inc., Deep Blue Medical Advances, Inc., Track X Technology, and Istari Oncology, Inc. He is a member of the advisory boards for several companies, including Valence Advantage Life Sciences Fund and Centre Partners. Mr. Bonczek received an AB in chemistry and a JD degree from the University of North Carolina. He also holds an MBA from the Wharton School at the University of Pennsylvania.
Thomas F. Tedder, PhD
Dr. Tedder received his PhD in molecular cell biology from the University of Alabama at Birmingham, where he was an American Society for Microbiology President’s Fellow. He was a Damon Runyon-Walter Winchell Research Fellow at Harvard Medical School and Dana-Farber Cancer Institute and joined the faculty in 1985, rising to Associate Professor and principal investigator in the Division of Tumor Immunology at Dana-Farber Cancer Institute. In 1993, Dr. Tedder became the inaugural chairman and professor of Duke University Medical Center’s Department of Immunology and served as director of the Duke Comprehensive Cancer Center Immunobiology Program. He was a Scholar of the Leukemia Society of America and received the LeRoy Collins Distinguished Alumni Award, an NCI/NIH Shannon Award, the Stohlman Scholarship, the Leukemia Society's highest award for research in the field of hematology/oncology, and the Alter Geller Professorship for Research in Immunology at Duke. He founded Cellective Therapeutics in 2003 with the largest Series A financing in the Southeast at that time. The company was acquired by MedImmune/AstraZeneca in 2005. In 2015, he founded Cellective BioTherapy, Inc. and serves as CEO and a director. Dr. Tedder has and continues to serve as a consultant and SAB member to more than 20 national and international biopharmaceutical companies and private foundations. He has authored over 400 scientific papers and was recognized as an ISI “100 Most-Cited Authors” in the field of immunology. Dr. Tedder holds 25 patents issued in the U.S.
Sailash Patel, MBA - Board Advisor
Mr. Patel serves a board member at Meryx, Inc. and has more than 20 years of experience in the pharmaceutical industry, including leadership roles in start-up and multinational companies. He served as the Chief Financial Officer and Vice President of Strategic Development for Furiex Pharmaceuticals, where he led core business and finance functions. Prior to that, Mr. Patel was the General Manager of BioDuro, a PPD, Inc. company, where he was responsible for all functional aspects of a 700 employee China-based drug discovery unit, providing integrated discovery services to the pharmaceutical industry. Prior to BioDuro, he served as the Vice President of Strategic Development at PPD, where he was responsible for corporate strategic planning, mergers and acquisitions, and compound partnering business development. He holds an MBA from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill and a bachelor's degree in pharmacy with honors from the University of Nottingham in the U.K.
Seth Rudnick, MD - Board Advisor
Dr. Rudnick has extensive expertise in oncology, drug discovery and development, and healthcare investments. He is the Chairman of the Board of Directors of G1 Therapeutics, Inc. and is a member of its advisory board. Dr. Rudnick recently retired from Canaan Partners, where he built the global venture capital firm's capability in biopharmaceutical investing. Prior to joining Canaan, he was the CEO and Chairman of CytoTherapeutics, a developer of cell therapies to combat chronic diseases. He also helped start and led the development of Ortho Biotech, a division of Johnson & Johnson. Earlier in his career, Dr. Rudnick worked at Schering-Plough and directed pharmaceutical development efforts at Biogen. Dr. Rudnick was a Yale Fellow and Robert Wood Johnson scholar in medical oncology. He earned his medical degree at the University of Virginia and holds a BA in history from the University of Pennsylvania. He is a Clinical Professor of Medicine at the University of North Carolina at Chapel Hill, teaching and advising faculty members on biotechnology issues. He also currently serves as the Chairman of Liquidia Technologies and Meryx and a board member at Abyrx.